Serum oxidatives stress parameters and homocysteine levels in patients with renal transplant

Farmacia

Volumn 56, Issue 3, 2008, Pages 352-358

  Antonescu, Angela ^a   Mureşan, Mariana ^a   Micle, Otilia ^a   Micle, Liana ^a   Dobjanschi, Luciana ^a   Vicaş, Laura ^a   Dorofteiu, M ^b  

^a Faculty Of Pharmacy   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPID PEROXIDE; MALONALDEHYDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

AMINO ACID BLOOD LEVEL; ARTICLE; CALORIMETRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYMATIC ASSAY; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; OXIDATIVE STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 45949085677     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cayatte AJ, Polacino JJ, Horten K, Cohen CA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14:753-759
2. Chen L., Ingrid S., Ding Y.G., Liu Y., Qi J.-G., Tang C.-S., Du J.-B. - Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chinese Medical Journal, 2007, vol. 120, 5, 389-393
3. Danishpajooh IO, Gudi T, Chen Y, Kharitonov VG, Sharma VS, Boss GR. Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway. J Biol Chem 2001; 276:27296-27303
4. Domagata TB, Libura M, Szczeklik A: Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411-416
5. Ducloux D, Motte G, Challier B, Gibey R and Chalopin JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134-137
6. Ducloux D, Ruedin C, Gibey V, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM: Prevalence, determinants, and clinical significance of hypethomocysteinemia in renal transplant recipients. Nephrol Dial Transplant, 1998; 13:2890-2893
7. Hankey G.J., Eikelboom J.W. - Homocysteine and vascular disease. Lancet 1999; 354:407-13
8. Kai-Chung Tse, Man-Fai Lam, Pok-Siu Yip, Fu-Keung Li, Kar-Neng Lai and Tak-Mao Chan: A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004: 18:274-280
9. Marubayashi S, Ohdan H, Tashiro H, Tokita D, Onoe T, Hayamizu K, Asahara T, Doi S, Okumoto S, Tanji C, Kawai T, Taniguchi Y, Fukuda Y, Dohi K: Studies on post-transplant dyslipidemia in kidney transplant patients. Hiroshima J Med Sci. 2005; 54(2):39-45
10. Massy ZA, Chadefaux-Vekemans B, Chevalier A: Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Ttransplant 1994; 9: 1103-1106
11. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. 1993; 329:2002-2012
12. Smith C., Marks A.D., Lieberman M. - Mark's basic medical biochemistry a clinical approach second edition- Lippincott W. and Wilkins, 2005
13. van Guldener C: Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?. Nephrology Dialysis Transplantation 2006 21(5):1161-1166
14. Welch GN, Loscalzo J. - Homocysteine, and atherothrombosis. N Engl J Med 1998; 338:1042-50
15. Winkelmayer WC, Kramar R, Curhan GC et al. Fasting plasma total homocysteine levels and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 2005; 16; 225-260.